Synthetic Male Condom Slippage-Breakage Study

Sponsor
Church & Dwight Company, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05370196
Collaborator
Essential Access Health (Other)
600
2
2
7.8
300
38.7

Study Details

Study Description

Brief Summary

This is a multi-site, double-blind, crossover, randomized phase II study to evaluate the functional performance of a synthetic male condom as compared to a marketed latex condom.

Condition or Disease Intervention/Treatment Phase
  • Device: Test Product
  • Device: Control Product
N/A

Detailed Description

Approximately 300 heterosexual monogamous couples not at risk of pregnancy or transmission of sexually transmitted infections (STI) will be recruited to use both the test (synthetic) condom and a control (latex) condom. Couples will be given 4 condoms of one type (randomly determined) to use over a two week period, followed by 4 condoms of the other type to be used over the next two week period. The number of clinical failures (either condom breaks or completely slips off the penis) for each condom type will be compared to determine whether the test condom is non-inferior to the control condom. The study plan is based on International Standards Organization (ISO) guidance document ISO 29943-1 with the action standard set by synthetic condom standard ISO 23409.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Each product will be labeled with a randomly generated code.
Primary Purpose:
Prevention
Official Title:
Evaluation of the Functional Performance and Acceptability of a Synthetic Male Condom as Compared to a Commercial Latex Condom (Trojan-Enz)
Actual Study Start Date :
Jun 10, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Test Product

Synthetic Male Condom

Device: Test Product
Synthetic Male Condom
Other Names:
  • Synthetic Male Condom
  • Active Comparator: Control Product

    Latex Male Condom

    Device: Control Product
    Latex Male Condom
    Other Names:
  • Latex Male Condom
  • Outcome Measures

    Primary Outcome Measures

    1. Total Clinical Failure Rate [Throughout the study. Each participating couple will engage in 8 acts over a 4 week period.]

      The number of condoms that broke or slipped completely off the penis during intercourse or withdrawal divided by the number of condoms used for vaginal intercourse.

    Secondary Outcome Measures

    1. Clinical Breakage Rate [Throughout the study. Each participating couple will engage in 8 acts over a 4 week period.]

      The number of condoms that broke during intercourse or withdrawal divided by the number of condoms used for vaginal intercourse.

    2. Clinical Complete Slippage Rate [Throughout the study. Each participating couple will engage in 8 acts over a 4 week period.]

      The number of condoms that slipped completely off the penis during intercourse or withdrawal divided by the number of condoms used for vaginal intercourse.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Willing and able to give written or electronic informed consent

    • Willing to respond to questions concerning participant's reproductive and contraceptive history and use of condoms contained either on self-administered surveys or interviews

    • Agree to have vaginal intercourse at least once weekly

    • Protected against pregnancy by oral contraceptives, an intrauterine device (IUD), an implant, contraceptive injections, contraceptive patch, or sterilization (tubal ligation or vasectomy)

    • Willing to use the study products for eight acts of vaginal intercourse within four weeks of study entry

    • In a mutually monogamous relationship with participant's study partner for at least 3 months prior to screening and be willing to remain mutually monogamous throughout study participation

    • Agree not to use any vaginal or sexual lubricant except the product supplied by the study (AstroglideTM)

    • Agree not to wear any genital piercing jewellery while using the study condoms

    • Agree not to use sex toys or drugs intended to enhance or diminish sexual response when using study condoms

    • Agree to return any unopened condoms

    • Reachable by telephone

    • Has home internet access, a valid personal email for each partner, ability to videoconference and use electronic signature technology

    • Male partner agrees to ejaculate during vaginal intercourse

    Exclusion Criteria:
    • Currently participating in another similar clinical study or employed by a condom manufacturer or Essential Access Health

    • Female partner self-reported as pregnant

    • Allergic to natural rubber latex or styrene-isoprene-styrene (SIS), or has a history of recurrent adverse events following use of latex or SIS products

    • Unable to follow instructions or strictly adhere to the visit schedule

    • At significant (high) risk of sexually transmitted infections, including human immunodeficiency virus (HIV) infection or having a medical history of recurrent, serious sexually transmitted infection (e.g., gonorrhea, syphilis, Chlamydia)

    • Currently using condoms for protection against a known sexually transmitted infection

    • Taking any externally applied medication or oral medication to treat a genital condition

    • Male partner has had difficulty achieving or maintaining an erection or achieving ejaculation in the last month prior to screening under typical circumstances/ conditions.

    • Any self-reported genital condition (e.g., itching, burning, irritation, etc.) which, in the opinion of the investigator, could affect the use of the study condoms or the ability to interpret study data

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Essential Access Health Berkeley California United States 94710
    2 Essential Access Health Los Angeles California United States 90010

    Sponsors and Collaborators

    • Church & Dwight Company, Inc.
    • Essential Access Health

    Investigators

    • Principal Investigator: Terri Walsh, MPH, Essential Access Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Church & Dwight Company, Inc.
    ClinicalTrials.gov Identifier:
    NCT05370196
    Other Study ID Numbers:
    • ST-21-U71
    First Posted:
    May 11, 2022
    Last Update Posted:
    Aug 11, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by Church & Dwight Company, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 11, 2022